Report Detail

Pharma & Healthcare Global Cemiplimab-rwlc Market Insights, Forecast to 2025

  • RnM3518059
  • |
  • 12 June, 2019
  • |
  • Global
  • |
  • 119 pages
  • |
  • QYResearch
  • |
  • Pharma & Healthcare

Global Cemiplimab-rwlc Market Insights, Forecast to 2025

Table of Contents

    1 Study Coverage

    • 1.1 Cemiplimab-rwlc Product
    • 1.2 Market Segments
    • 1.3 Key Manufacturers Covered
    • 1.4 Market by Type
      • 1.4.1 Global Cemiplimab-rwlc Market Size Growth Rate by Product
      • 1.4.2 350 mg Injection
      • 1.4.3 Type II
    • 1.5 Market by End User
      • 1.5.1 Global Cemiplimab-rwlc Market Size Growth Rate by End User
      • 1.5.2 Metastatic cutaneous squamous cell carcinoma (CSCC)
      • 1.5.3 Locally advanced CSCC
    • 1.6 Study Objectives
    • 1.7 Years Considered

    2 Executive Summary

    • 2.1 Global Cemiplimab-rwlc Market Size
      • 2.1.1 Global Cemiplimab-rwlc Revenue 2014-2025
      • 2.1.2 Global Cemiplimab-rwlc Sales 2014-2025
    • 2.2 Cemiplimab-rwlc Growth Rate by Regions
      • 2.2.1 Global Cemiplimab-rwlc Sales by Regions
      • 2.2.2 Global Cemiplimab-rwlc Revenue by Regions

    3 Breakdown Data by Manufacturers

    • 3.1 Cemiplimab-rwlc Sales by Manufacturers
      • 3.1.1 Cemiplimab-rwlc Sales by Manufacturers
      • 3.1.2 Cemiplimab-rwlc Sales Market Share by Manufacturers
      • 3.1.3 Global Cemiplimab-rwlc Market Concentration Ratio (CR5 and HHI)
    • 3.2 Cemiplimab-rwlc Revenue by Manufacturers
      • 3.2.1 Cemiplimab-rwlc Revenue by Manufacturers (2014-2019)
      • 3.2.2 Cemiplimab-rwlc Revenue Share by Manufacturers (2014-2019)
    • 3.3 Cemiplimab-rwlc Price by Manufacturers
    • 3.4 Cemiplimab-rwlc Manufacturing Base Distribution, Product Types
      • 3.4.1 Cemiplimab-rwlc Manufacturers Manufacturing Base Distribution, Headquarters
      • 3.4.2 Manufacturers Cemiplimab-rwlc Product Type
      • 3.4.3 Date of International Manufacturers Enter into Cemiplimab-rwlc Market
    • 3.5 Manufacturers Mergers & Acquisitions, Expansion Plans

    4 Breakdown Data by Product

    • 4.1 Global Cemiplimab-rwlc Sales by Product
    • 4.2 Global Cemiplimab-rwlc Revenue by Product
    • 4.3 Cemiplimab-rwlc Price by Product

    5 Breakdown Data by End User

    • 5.1 Overview
    • 5.2 Global Cemiplimab-rwlc Breakdown Data by End User

    6 North America

    • 6.1 North America Cemiplimab-rwlc by Countries
      • 6.1.1 North America Cemiplimab-rwlc Sales by Countries
      • 6.1.2 North America Cemiplimab-rwlc Revenue by Countries
      • 6.1.3 United States
      • 6.1.4 Canada
      • 6.1.5 Mexico
    • 6.2 North America Cemiplimab-rwlc by Product
    • 6.3 North America Cemiplimab-rwlc by End User

    7 Europe

    • 7.1 Europe Cemiplimab-rwlc by Countries
      • 7.1.1 Europe Cemiplimab-rwlc Sales by Countries
      • 7.1.2 Europe Cemiplimab-rwlc Revenue by Countries
      • 7.1.3 Germany
      • 7.1.4 France
      • 7.1.5 UK
      • 7.1.6 Italy
      • 7.1.7 Russia
    • 7.2 Europe Cemiplimab-rwlc by Product
    • 7.3 Europe Cemiplimab-rwlc by End User

    8 Asia Pacific

    • 8.1 Asia Pacific Cemiplimab-rwlc by Countries
      • 8.1.1 Asia Pacific Cemiplimab-rwlc Sales by Countries
      • 8.1.2 Asia Pacific Cemiplimab-rwlc Revenue by Countries
      • 8.1.3 China
      • 8.1.4 Japan
      • 8.1.5 Korea
      • 8.1.6 India
      • 8.1.7 Australia
      • 8.1.8 Indonesia
      • 8.1.9 Malaysia
      • 8.1.10 Philippines
      • 8.1.11 Thailand
      • 8.1.12 Vietnam
      • 8.1.13 Singapore
    • 8.2 Asia Pacific Cemiplimab-rwlc by Product
    • 8.3 Asia Pacific Cemiplimab-rwlc by End User

    9 Central & South America

    • 9.1 Central & South America Cemiplimab-rwlc by Countries
      • 9.1.1 Central & South America Cemiplimab-rwlc Sales by Countries
      • 9.1.2 Central & South America Cemiplimab-rwlc Revenue by Countries
      • 9.1.3 Brazil
    • 9.2 Central & South America Cemiplimab-rwlc by Product
    • 9.3 Central & South America Cemiplimab-rwlc by End User

    10 Middle East and Africa

    • 10.1 Middle East and Africa Cemiplimab-rwlc by Countries
      • 10.1.1 Middle East and Africa Cemiplimab-rwlc Sales by Countries
      • 10.1.2 Middle East and Africa Cemiplimab-rwlc Revenue by Countries
      • 10.1.3 GCC Countries
      • 10.1.4 Turkey
      • 10.1.5 Egypt
      • 10.1.6 South Africa
    • 10.2 Middle East and Africa Cemiplimab-rwlc by Product
    • 10.3 Middle East and Africa Cemiplimab-rwlc by End User

    11 Company Profiles

    • 11.1 Sanofi
      • 11.1.1 Sanofi Company Details
      • 11.1.2 Company Business Overview
      • 11.1.3 Sanofi Cemiplimab-rwlc Sales, Revenue and Gross Margin (2014-2019)
      • 11.1.4 Sanofi Cemiplimab-rwlc Products Offered
      • 11.1.5 Sanofi Recent Development

    12 Future Forecast

    • 12.1 Cemiplimab-rwlc Market Forecast by Regions
      • 12.1.1 Global Cemiplimab-rwlc Sales Forecast by Regions 2019-2025
      • 12.1.2 Global Cemiplimab-rwlc Revenue Forecast by Regions 2019-2025
    • 12.2 Cemiplimab-rwlc Market Forecast by Product
      • 12.2.1 Global Cemiplimab-rwlc Sales Forecast by Product 2019-2025
      • 12.2.2 Global Cemiplimab-rwlc Revenue Forecast by Product 2019-2025
    • 12.3 Cemiplimab-rwlc Market Forecast by End User
    • 12.4 North America Cemiplimab-rwlc Forecast
    • 12.5 Europe Cemiplimab-rwlc Forecast
    • 12.6 Asia Pacific Cemiplimab-rwlc Forecast
    • 12.7 Central & South America Cemiplimab-rwlc Forecast
    • 12.8 Middle East and Africa Cemiplimab-rwlc Forecast

    13 Market Opportunities, Challenges, Risks and Influences Factors Analysis

    • 13.1 Market Opportunities and Drivers
    • 13.2 Market Challenges
    • 13.3 Market Risks/Restraints
    • 13.4 Macroscopic Indicators

    14 Value Chain and Sales Channels Analysis

    • 14.1 Value Chain Analysis
    • 14.2 Cemiplimab-rwlc Customers
    • 14.3 Sales Channels Analysis
      • 14.3.1 Sales Channels
      • 14.3.2 Distributors

    15 Research Findings and Conclusion

      16 Appendix

      • 16.1 Research Methodology
        • 16.1.1 Methodology/Research Approach
        • 16.1.2 Data Source
      • 16.2 Author Details

      LIBTAYO(Cemiplimab-rwlc)® is a programmed death receptor-1 (PD-1) blocking antibody indicated for the treatment of patients with metastatic cutaneous squamous cell carcinoma (CSCC) or locally advanced CSCC who are not candidates for curative surgery or curative radiation.
      The global Cemiplimab-rwlc market is valued at xx million US$ in 2018 and will reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025. The objectives of this study are to define, segment, and project the size of the Cemiplimab-rwlc market based on company, product type, end user and key regions.

      This report studies the global market size of Cemiplimab-rwlc in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Cemiplimab-rwlc in these regions.
      This research report categorizes the global Cemiplimab-rwlc market by top players/brands, region, type and end user. This report also studies the global Cemiplimab-rwlc market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.

      The following manufacturers are covered in this report, with sales, revenue, market share for each company:
      Sanofi

      Market size by Product
      350 mg Injection
      Type II
      Market size by End User
      Metastatic cutaneous squamous cell carcinoma (CSCC)
      Locally advanced CSCC

      Market size by Region
      North America
      United States
      Canada
      Mexico
      Asia-Pacific
      China
      India
      Japan
      South Korea
      Australia
      Indonesia
      Singapore
      Malaysia
      Philippines
      Thailand
      Vietnam
      Europe
      Germany
      France
      UK
      Italy
      Spain
      Russia
      Central & South America
      Brazil
      Rest of Central & South America
      Middle East & Africa
      GCC Countries
      Turkey
      Egypt
      South Africa

      The study objectives of this report are:
      To study and analyze the global Cemiplimab-rwlc market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025.
      To understand the structure of Cemiplimab-rwlc market by identifying its various subsegments.
      To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
      Focuses on the key global Cemiplimab-rwlc companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.
      To project the value and sales volume of Cemiplimab-rwlc submarkets, with respect to key regions.
      To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

      In this study, the years considered to estimate the market size of Cemiplimab-rwlc are as follows:
      History Year: 2014-2018
      Base Year: 2018
      Estimated Year: 2019
      Forecast Year 2019 to 2025

      This report includes the estimation of market size for value (million US$) and volume (K Units). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Cemiplimab-rwlc market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.

      For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.


      Summary:
      Get latest Market Research Reports on Cemiplimab-rwlc . Industry analysis & Market Report on Cemiplimab-rwlc is a syndicated market report, published as Global Cemiplimab-rwlc Market Insights, Forecast to 2025. It is complete Research Study and Industry Analysis of Cemiplimab-rwlc market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.


      REPORT YOU MIGHT BE INTERESTED

      Purchase this Report

      $3,900.00
      $5,850.00
      $7,800.00
      3,099.86
      4,649.80
      6,199.73
      3,475.07
      5,212.61
      6,950.14
      423,395.70
      635,093.55
      846,791.40
      272,483.25
      408,724.88
      544,966.50
      Credit card Logo

      Related Reports


      Reason to Buy

      Request for Sample of this report